These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://poppieqnkz053345.canariblogs.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-53919111